Teva to build in Russia; Hospital wastewater studied for drug elimination;

> Teva ($TEVA) will invest $50 million to build a pharma plant in Yaroslavl, Russia. Story

> A full-scale trial for the treatment of hospital wastewater to eliminate pharmaceuticals is under way in Europe. Article

> Drug Process Licensing Associates has filed a process patent for sitagliptin, the active ingredient in Merck's ($MRK) diabetes drug Januvia, protecting the manufacturing process for 20 years. Release

> In response to the shortage of talent in the pharmaceutical labor market, a Maltese University has launched a B.S. degree program covering manufacturing and sales. Item

> "Biofilters and single-use technology did particularly well," Pall's ($PLL) CEO told analysts, explaining why consumable sales grew almost 12% in the fourth quarter. More

> Rabies vaccinations that left two Delhi residents severely ill came from a new lot of vials; the remainder has been sealed. Story

> "CMO quality agreements are like marriage contracts. If you have to consistently pull them out when having conversations, then you are likely headed for divorce and should consider finding another CMO," says Susan Schniepp of OSO Biopharmaceuticals. Blog

> Nigerian pharmaceutical manufacturers that follow global standards and best practices are in line to be certified by WHO. Story

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.